Slide 1: Fourth Quarter and Fiscal Year 2011 Conference Call and Webinar
Simulations Plus, Inc. (NASDAQ:SLP) Fourth Quarter and Fiscal Year 2011 Conference Call and Webinar December 1, 2011
Slide 2: Safe Harbor Statement
With the exception of historical information, the matters discussed in this presentation are forward-looking statements that involve a number of risks and uncertainties. The actual results of the Company could differ significantly from those statements. Factors that could cause or contribute to such
Slide 3: SLP 4Q11 Highlights
• 4Q11 compared to 4Q10: – 16 th consecutive profitable quarter (38 of last 40 were profitable) – 4Q11 sales lower 3.9% to $2.12 million from $2.21 million – Words+ subsidiary sales down 20.5% – Net Income down 46.3% to $0.186 million from $0.345 million – Diluted earnings per share down 44.4% to $0
Slide 4: simulations pi:
$28 $24) $2.1$21 a2 a3 = 2008 ™ 2009" 2010" 2011 simulations pi:
Slide 5: Quarterly Revenues and Annual Revenues
Quarterly Revenues Annual Revenues WRC RRR, Pharmaceutical = Words+ 2007 2008 200920102011 ‘=Pharmaceutical ™ Words+ simulationsplus, inc, é
Slide 6: Gross Margin (consolidated)
Gross Margin (consolidated) 75.6% 78.9% 78.8% 70.4% 73.8% 74.4% 80.0% 67.9% 75.0% 76.3% 77.6% 75.6% 73.6% 77.6% 76.3% 73.0%
Slide 7: Income Before Taxes (consolidated)
Income Before Taxes (consolidated)
Slide 8: Net Income by Division
Net Income by Division $243K $565K $764K $165K $312K $368K $569K $163K $430K $641K $740K $345K $567K $907K $1.054 M $185K
Slide 9: Consolidated Income Statement 4QFY11 vs 4QFY10
4Q11 4Q10 Pharmaceutical software and services revenue 1.427 1.334 Words+ revenue 0.693 0.872 Consolidated revenue 2.120 2.206 Gross profit 1.547 1.667 Gross profit margin 73.0% 75.6% SG&A 1.199 1.115 R&D 0.234 0.222 Total operating expenses 1.433 1.337 Income before income taxes 0.172 0.357 Net inc
Slide 10: Selected Balance Sheet Items
August 31, 2011 August 31, 2010 Cash and cash equivalents $10.181 $9.631 Total current assets 13.275 12.390 Total assets $15.867 $14.660 Total current liabilities 1.141 1.204 Total liabilities 1.830 1.615 Shareholders’ equity 14.036 13.045 Total liabilities and shareholders’ equity 15.867 14.660 Sel
Slide 11: Sale of Words+ Subsidiary
• The sale of our Words+ subsidiary was closed on November 30, 2011 • Proceeds after adjusting for changes in Net Working Capital from August 31, 2011 were $1 . 98 million • This sale is expected to have the following effects: – Reduce our employee count to 24 from 39 – Reduce our auditing and legal
Slide 12: Sale of Words+ Subsidiary
• Going forward, Words+ will be reported as “discontinued operations” • The next slides show the past financial performance of the pharmaceutical software and services business by itself to provide an indication of how the business will be reported from now on • Adjustments to these numbers for chan
Slide 13: Pharmaceutical Software & Services Revenues by Quarter
Pharmaceutical Software & Services Revenues by Quarter $3 81.4814 $17 $26 $23 $2.0 $20 S14 $13) s11st4 = 2008 2010 2011 simulationsplus, inc. ¢
Slide 14: Pharmaceutical Software & Services Revenues by Fiscal Year
Pharmaceutical Software & Services Revenues by Fiscal Year
Slide 15: Pharmaceutical Software & Services Net Income by Quarter
Pharmaceutical Software & Services Net Income by Quarter
Slide 16: Pharmaceutical Software & Services Net Income by Fiscal Year
Pharmaceutical Software & Services Net Income by Fiscal Year
Slide 17: Marketing and Sales Program
Marketing and Sales Program • Conferences/Scientific Meetings • Training Workshops • Posters, Presentations, and Peer-Reviewed Publications • Strategic Digital Marketing Initiatives • Collaborations/Consulting/Grants – Progressing on our 5-year collaboration with the FDA Center for Food Safety and A
Slide 18: Ongoing Enhancements
• Simulations Plus continues to increase its technological advantage Ongoing Enhancements • Version 8.0 release expected in December 2011 - major upgrade • Expanded drug-drug interaction to include transporters and induction • Expanded PDPlus™ pharmacodynamics modeling module • Expanded ocular deliv
Slide 19: Summary
Summary • For FY11: • Revenues = $11.8 million ( up 9.4% ) • Net Income = $2.71 million ( up 25.9% ) • Earnings/share = $0.17 ( up 29.3% ) • Cash = $10.2 million ( up 5.7% after share repurchases of $2.07) • Continuing to Expand our Life Sciences team: • To promote faster development of new products
Slide 20: Simulations Plus, Inc.
simulations plus, inc. é